Expands Celltrion's Reach in Italy with Immunomodulatory and Antineoplastic Pharmaceuticals
Celltrion's Autoimmune and Anticancer Drugs Gain Ground in Italy
South Korean biopharmaceutical company, Celltrion, has made a significant impact in Italy's pharmaceutical market in the first half of 2025. The company has secured seven contracts, primarily for the supply of its autoimmune drug, Steqeyma, in the regions of Veneto, Trentino-Alto Adige, Sardinia, Lazio, and Umbria.
In the Lazio and Umbria regions, Celltrion's autoimmune drug, Uyplima (adalimumab), holds a market share of 52%. Yuflyma (adalimumab), another autoimmune treatment, has achieved a 52% market share in Italy, marking a 5-point increase quarter-over-quarter.
Celltrion's anticancer drugs, Truxima (rituximab) and Vegzelma (bevacizumab), have also made their mark in these regions. While specific market shares for these drugs are not detailed, they, along with the breast and stomach cancer treatment, Herzuma (trastuzumab), collectively hold market shares between 29% and 30%.
Truxima and Vegzelma have been awarded contracts in the Lazio and Umbria regions, with Vegzelma securing a 30% market share in Umbria. Another anticancer drug by Celltrion, Vegzelma, also won a bid in the state of Umbria.
Celltrion's general manager for the Italian office, Yoo Won-sik, stated that the company's autoimmune treatments and anticancer drugs are expanding their influence in Italy. IQVIA estimates that Remsima and Remsima SC combined for 66 percent of the Italian autoimmune drug market in the first quarter.
Remsima, another autoimmune drug by Celltrion, has secured contracts in Umbria and Puglia in Italy. Remsima SC is currently being sold in all 20 states in Italy.
Celltrion plans to launch new products and score more orders in the second half of the year to expand the prescription of their products and keep up the growth of performance. The company also aims to expand its presence in Italy with these contracts.
Celltrion expects to keep supplying anticancer drugs in Italy as more bids are scheduled in the second half of the year. Steqeyma, Celltrion's autoimmune drug, was launched in Italy in January 2025, and the company plans to supply it to these regions through May.
Celltrion's autoimmune treatments and anticancer drugs are gaining influence in Italy's medical industry, a key pharmaceutical market in Europe. The rapid success of Celltrion's drugs in Italy underscores the company's commitment to delivering high-quality treatments to patients around the world.
[1] Source: Celltrion press release, Q2 2025 [2] Source: IQVIA Market Analysis, Q1 2025
- In the medical-conditions sector, Celltrion's autoimmune drug, Steqeyma, has gained substantial market shares in multiple regions of Italy, such as Veneto, Trentino-Alto Adige, Sardinia, Lazio, and Umbria.
- Notably, Celltrion's anticancer drugs, Truxima, Vegzelma, and Herzuma, have collectively secured significant market shares in Italy, with specific shares ranging from 29% to 30%.
- In the finance and business realm, Celltrion has secured several contracts for its autoimmune and anticancer drugs, aiming to expand the prescription of their products and maintain growth in the Italian market.
- The health-and-wellness industry in Italy has seen the impact of Celltrion's drugs, as Celltrion plans to continue supplying autoimmune and anticancer treatments in the second half of the year, with the intention of expanding their presence further in the Italian market.
